Meeting people can be hard enough as it is. A hepatitis C blood test can help diagnose the condition and create a treatment plan. Learn about the hepatitis C blood test and what it can tell you. Rheumatoid arthritis RA is an autoimmune disease that mainly attacks the synovial tissues around the joints. Learn the prevalence, risk factors….
Alcoholic hepatitis is an inflammatory condition of the liver. Get the facts on possible risk factors, complications, and treatment options. Hepatitis refers to an inflammatory condition of the liver. It's commonly caused by a viral infection, but there are other possible causes of…. The latest hep C treatments are easier to take, cause fewer side effects, work faster, and are more effective.
Learn more about your treatment options…. Virol J. AIDS Care. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. Indian J Med Res. The declining risk of post-transfusion hepatitis C virus infection. Prevalence and significance of hepatitis C HCV seropositivity in blood donors. Diversity of genotype and mode of spread of Hepatitis C virus in Northern India.
Saudi J Gastroenterol. Distribution pattern of HCV genotypes and its association with viral load. New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India. Arch Virol. Prevalence and geographic distribution of hepatitis C genotypes in Indian patient cohort.
Infect Genet Evol. Indian J Med Microbiol. The prevalence of hepatitis B and hepatitis C virus infection among patients with chronic liver disease in south India. Int J Infect Dis. The natural history of hepatitis C HCV infection. Int J Med Sci. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: Past, present, and future.
J Gastroenterol. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. The continuing risk of transfusion-transmitted infections.
Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis. Vox Sang. Morishima C, Gretch DR. Clinical use of Hepatitis C virus test for the diagnosis and monitoring during therapy. Clin Liver Dis. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature.
J Viral Hepat. J Med Virol. Centres for Disease Control and Prevention. Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection.
J Clin Microbiol. Significance of the signal-to-cutoff ratios of anti-hepatitis C enzyme immunoassays in screening of Chinese blood donors. Efficiency of the Ortho VITROS Assay for the detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios.
The role of core antigen detection in management of hepatitis C: A critical review. J Clin Virol. Usefulness of the hepatitis C core antigen assay for screening a population undergoing routine medical checkup. J Clin Chem. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen.
J Virol Methods. Acute hepatitis C infection. Dynamics of viremia in early hepatitis C virus infection. Kamal SM. Acute hepatitis C: A systematic review. Am J Gastroenterol. Molecular diagnostics of hepatitis C virus infection: A systematic review. World Health Organization; Screening donated blood for transfusion-transmissible infections: Recommendations. When you have been exposed to hepatitis C, your body makes antibodies to the virus.
These antibodies circulate in your bloodstream for many years, perhaps even throughout your lifetime. The virus is spread through direct contact with infected blood.
Routine screening is done for people who are at higher risk of contracting it, such as those who use injection drugs and baby boomers who were born between and Your blood will also be tested if you donate blood, as blood transfusions can transmit the hepatitis C virus. If you submit donor blood that tests positive for HCV antibodies, it will be rejected and you will be permanently banned from donating blood in order to protect people who receive blood transfusions.
If you are looking at older laboratory results in your medical record, you may see the Hepatitis C RIBA test reported. In past years, the first ELISA tests that were performed to look for the hepatitis C antibody often had false positives , meaning that they showed a positive result when you actually didn't have any hepatitis C antibody. As a result, it was necessary to double-check every positive result with a secondary or confirmation test that was more specific.
If, however, the RIBA test came back negative, your healthcare provider may have ordered other tests to ensure that you didn't have HCV, depending on whether you were showing signs of the disease or you had a condition that might affect the accuracy of the tests.
The RIBA test may still be in use in other situations, such as in blood banking. Donor blood samples are screened for HCV, and a positive sample may be retested to confirm that it shows the hepatitis C virus.
RIBA has been commonly used as that confirmation test, but as technology evolves it may be replaced with other tests. Within genotype 1, it is also important to determine whether the patient is subtype 1a or 1b, as this determines treatment duration and the need for ribavirin in the treatment regimen.
Patients only need to be genotype tested once in their lifetime, as the genotype remains the same throughout the course of infection. Repeating a genotype test is warranted only if there is suspicion that a patient may have been reinfected with a different genotype after achieving an SVR. Genotype testing is performed by analyzing the sequences of various regions of the HCV genome. Most genotype assays rely on the amplification of short HCV RNA regions from clinical specimens, followed by a type-specific assay, such as restriction fragment length polymorphism RFLP analysis, line probe reverse hybridization, or sequence analysis.
Most assays target the 5' untranslated region 5' UTR , as it is the most conserved region throughout the HCV genome and is most suitable for reverse transcription polymerase chain reaction RT-PCR amplification.
DAAs are drugs that target specific steps in the life cycle of the hepatitis C virus. When these steps are disrupted, replication of HCV is stopped. RAV testing is occasionally done in treatment-naive patients if it may change the regimen or the duration of treatment. Veterans Crisis Line: Press 1. Complete Directory. If you are in crisis or having thoughts of suicide, visit VeteransCrisisLine.
0コメント